Corpus Intelligence IC Memo — THE CHILDRENS HOSPITAL OF PHILADELP 2026-04-26 03:45 UTC
IC Memo — THE CHILDRENS HOSPITAL OF PHILADELP
Investment Committee Memorandum | PA | 667 beds | Grade C | EBITDA uplift $198.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

THE CHILDRENS HOSPITAL OF PHILADELP

CCN 393303 | PHILADELPHIA, PA | 667 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

THE CHILDRENS HOSPITAL OF PHILADELP is a 667-bed large academic medical center in PHILADELPHIA, PA with $2.70B in net patient revenue and a -26.8% operating margin. The hospital serves a payer mix of 0.3% Medicare, 5.8% Medicaid, and 93.9% commercial.

Thesis: Undervalued. Our ML models identify $198.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -26.8% to -19.5% (+736bps).

Net Revenue HCRIS$2.70B
Current EBITDA COMPUTED$-722.6M
Operating Margin COMPUTED-26.8%
Occupancy HCRIS82.8%
Revenue / Bed COMPUTED$4.0M
Net-to-Gross HCRIS31.5%
Distress Probability ML37.9%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
26
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -26.8% places it below the state median. Among 26 size-comparable peers (334-1334 beds), the median margin is -8.8%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (334-1334), prioritizing same-state peers. 26 hospitals in the comp set.

HospitalStateBedsRevenueMargin
THE CHILDRENS HOSPITAL OF PHIL (Target)PA667$2.70B-26.8%
ST. LUKES HOSPITALPA633$8.94B87.9%
HOSPITAL OF THE UNIV OF PENNAPA1051$3.36B-12.8%
LEHIGH VALLEYPA1190$2.84B-5.9%
UPMC - PRESBYTERIAN SHADYSIDEPA1141$2.24B-23.0%
MILTON S. HERSHEY MEDICAL CENTPA616$2.08B-2.8%
TEMPLE UNIVERSITY HOSPITALPA761$1.99B0.8%
THOMAS JEFFERSON UNIV. HOSPITAPA868$1.93B-23.1%
GEISINGER MEDICAL CENTERPA525$1.58B4.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $198.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$56.6M+210bp18mo
Cost to Collect4.5%2.5%$53.9M+200bp12mo
Denial Rate Reduction12.0%6.5%$53.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$32.8M+122bp9mo
Clean Claim Rate88.0%96.0%$1.7M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$56.6M
Cost to Collect
$53.9M
Denial Rate Reduction
$53.4M
A/R Days Reduction
$32.8M
Clean Claim Rate
$1.7M
Total EBITDA Uplift$198.4M
Current EBITDA$-722.6M
+ RCM Uplift+$198.4M
Pro Forma EBITDA$-524.2M
Current Margin-26.8%
Pro Forma Margin-19.5%
WC Released (1x)$103.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-1.11B$-2.78B0.00x-100.0%
Base (11x exit)10.0x11.0x$-1.11B$-3.42B0.00x-100.0%
Bull Case9.0x11.0x$-1.00B$-3.13B0.00x-100.0%
Bull (12x exit)9.0x12.0x$-1.00B$-3.71B0.00x-100.0%
Bear Case11.0x10.0x$-1.22B$-3.41B0.00x-100.0%
Bear (11x exit)11.0x11.0x$-1.22B$-4.15B0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 26 hospitals with 334-1334 beds
  • Same-state prioritization (n=27)
  • Comp margins: P25=-20.2% / P50=-8.8% / P75=0.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.